

Biographies | Sandra Horning & Levi Garraway

Sandra J. Horning, M.D., FACP, FASCO

Dr. Sandra Horning was appointed Chief Medical Officer and Head of Global Product Development for Roche and Genentech in January 2014. She leads employees in the Product Development organization across the globe, oversees all aspects of late stage clinical development, and co-chairs the Late Stage Portfolio Committee that invests in pivotal registrational trials. During her tenure, she has received recognition for her industry contributions and overseen the successful development of 15 new molecular entities and numerous line extensions in oncology, hematology, neuroscience, ophthalmology, immunology and infectious disease.

Dr. Horning joined Roche and Genentech in late 2009 as Senior Vice President, Global Head of Clinical Science / Oncology and Hematology in the Product Development organization. Prior to that, she served as a tenured professor, practicing oncologist and investigator, and held multiple leadership positions including Vice-Chair of the Department of Medicine at Stanford University, where she is an Emerita Professor of Medicine (Oncology and Blood and Bone Marrow Transplantation). Dr. Horning has authored more than 300 peer-reviewed journal articles, book chapters, reviews and editorials, and has served on the editorial boards of multiple peer-reviewed medical journals. She was named a Best Doctor in America consecutively from 1992 - 2008 and served as Chairman of the Eastern Cooperative Oncology Group lymphoma committee and 2005 - 2006 President of the American Society of Clinical Oncology.

Dr. Horning received Bachelor of Arts and Doctor of Medicine degrees at the University of Iowa and completed post-doctoral training in internal medicine at the University of Rochester and in medical oncology at Stanford University.

Levi Garraway, M.D., Ph.D.

Dr. Levi Garraway, M.D., Ph.D., was most recently Eli Lilly's Senior Vice President, Oncology Research and Development & Lilly Research Laboratories Novel Target Research. He joined Eli Lilly in 2017 as Senior Vice President, Global Development and Medical Affairs for their Oncology division. Prior to that, Dr. Garraway was director of the Joint Center for Cancer Precision Medicine, which spanned Harvard teaching hospitals including the Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston Children's Hospital, and the Broad Institute of MIT and Harvard. He was also co-leader of the Cancer Genetics Program at the Dana-Farber / Harvard Cancer Center. In 2010, Dr. Garraway co-founded Foundation Medicine, the world's leading provider of tumor molecular information.

A Fellow of the American Association for Cancer Research (AACR), over the course of his career Dr. Garraway has served on the advisory boards of major cancer centers including Memorial Sloan Kettering and MD Anderson. He also served on several major National Institutes of Health (NIH) committees as well as the Blue Ribbon Panel for the Beau Biden Cancer Moonshot Initiative. Dr. Garraway was president of the American Society of Clinical Investigation from 2014 - 2015. He is the author of nearly 200 peer-reviewed scientific articles and has received many awards, including the Paul Marks Prize for Cancer Research, the Jane Cooke Wright Award from the AACR, the New Innovator Award from the NIH, and an Outstanding Investigator Award from the National Cancer Institute.

Dr. Garraway is a graduate of Harvard, where he earned his A.B., M.D., and his Ph.D. in Biological Chemistry and Molecular Pharmacology.